MDT · 10-Q · 2026Q3 · Full report
SPR Therapeutics Acquisition
Medtronic plc · 2026-09-03 · Importance 59 · Surprise 60 · In source text
Medtronic acquired all outstanding equity of privately held SPR Therapeutics, Inc. on July 16, 2026, for $654 million of total consideration transferred. The transaction strengthens the Neuromodulation division within the Neuroscience Portfolio. SPR’s temporary peripheral nerve stimulation technology is intended to enable earlier intervention for patients with chronic pain.
Key facts
- On July 16, 2026, Medtronic plc closed on the acquisition of all outstanding equity of SPR Therapeutics, Inc. for $654 million of total consideration transferred. source
- The SPR Therapeutics acquisition enhances the Neuromodulation division within the Neuroscience Portfolio with temporary peripheral nerve stimulation (PNS) technology. source
- Medtronic strengthened its Neuromodulation division through the SPR Therapeutics July 2026 acquisition to aid temporary peripheral nerve stimulation technology. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | negative | realized | -0.7% | On July 16, 2026, Medtronic plc closed on the acquisition of all outstanding equity of SPR Therapeutics, Inc. for $654 million of total… |
| assets | positive | realized | — | On July 16, 2026, Medtronic plc closed on the acquisition of all outstanding equity of SPR Therapeutics, Inc. for $654 million of total… |